Çѱ¹ÀÎ ´Ùȸ¼öÇ÷ÀÚÀÇ ºñ¿¹±âÇ×ü ¼±º°°Ë»ç¿¡¼ Dia Cell Æ÷ÇÔÇÑ 3% Surgiscreen Sub-Code D Æò°¡
Performance Evaluation of Unexpected Antibody Screening Test Including Dia Cell Using 3% Surgiscreen Sub-Code D in Korean Multi-Transfused Patients
´ëÇѼöÇ÷ÇÐȸÁö 2015³â 26±Ç 1È£ p.47 ~ p.53
ÀÌÁÖ¹Ì:Lee Ju-Mee
±è³²Èñ:Kim Nam-Hee/½Å°æÈ:Shin Kyung-Hwa/ÀÌÇöÁö:Lee Hyun-Ji/ÀåöÈÆ:Chang Chul-Hun L./ÀÌÀº¿±:Lee Eun-Yup/±èÇüȸ:Kim Hyung-Hoi
Abstract
¹è°æ: Çѱ¹Àο¡¼ ³ôÀº ºóµµ¸¦ º¸ÀÌ°í ÀÖ´Â Ç×-Dia Ç×ü´Â ºñ¿¹±âÇ×ü ¼±º°°Ë»ç ½Ã »óÇ°ÈµÈ ´ëºÎºÐÀÇ ¿Ü±¹»ê ÀûÇ÷±¸ ÆdzÚ(panel)¿¡´Â Æ÷ÇÔµÇÁö ¾Ê¾Æ ¼öÇ÷ ½Ã ¿ëÇ÷¹ÝÀÀÀ» ÀÏÀ¸Å³ °¡´É¼ºÀÌ ³ô´Ù. ÀÌ·¯ÇÑ ÀÌÀ¯·Î ºñ¿¹±âÇ×ü ¼±º°°Ë»ç¿¡¼ Dia¼±º°Ç÷±¸¸¦ Æ÷ÇÔÇØ¾ß ÇÒ Çʿ伺ÀÌ Á¦±âµÇ¾ú´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼´Â Dia¼±º°Ç÷±¸°¡ Æ÷ÇÔµÈ ºñ¿¹±âÇ×ü ¼±º°°Ë»ç¿¡¼ 2-Cell panelÀÎ ID-DiaCell I, II (DiaMed, Switzerland)¿Í Dia¼±º°Ç÷±¸(DiaMed, Switzerland)À» Ãß°¡·Î °Ë»çÇÏ´Â ±âÁ¸ÀÇ ¹æ¹ý°ú 3-Cell panel·Î Á¦ÀÛµÈ 3% Surgiscreen Sub-code D (Ortho-Clinical Diagnostics, USA)À» ºñ±³ÇÏ¿© ±× À¯¿ë¼ºÀ» Æò°¡ÇÏ¿´´Ù.
¹æ¹ý: 2013³â 12¿ù 13ÀϺÎÅÍ 2014³â 4¿ù 24ÀϱîÁö ´Ùȸ¼öÇ÷ÀÚ¸¦ ´ë»óÀ¸·Î 1885°³ÀÇ Ç÷Àå ¶Ç´Â Ç÷û °Ëü¸¦ ID-DiaCell°ú AutoVue Innova ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ 3% SurgiscreenÀÇ µÎ °¡Áö ½Ã¾àÀ¸·Î ºñ¿¹±âÇ×ü ¼±º°°Ë»ç¸¦ ½ÃÇàÇÏ¿´°í ¾ç¼º°á°ú¸¦ º¸ÀÌ´Â °Ëü¿¡ ´ëÇؼ´Â ºñ¿¹±âÇ×ü µ¿Á¤°Ë»ç¸¦ ½Ç½ÃÇÏ¿´´Ù.
°á°ú: ºñ¿¹±âÇ×ü ¾ç¼º·üÀº ID-DiaCell¿¡¼ 4.6% (87/1885)¿Í 3% Surgiscreen¿¡¼ 4.2% (79/1885)¸¦ º¸¿´´Ù. µÎ ½Ã¾àÀº 99.5%·Î ³ôÀº ÀÏÄ¡µµ¸¦ º¸¿´À¸¸ç, 10°ÇÀÇ ºÒÀÏÄ¡ °á°ú¸¦ º¸¿´°í 1°ÇÀº Surgiscreen¿¡¼¸¸ ¾ç¼º°á°ú¸¦ ³ªÅ¸³Â´Ù. ºñ¿¹±âÇ×ü Áß Ç×-Dia Ç×üÀÇ ¾ç¼ºÀ²Àº ID-DiaCell¿¡¼ 9.2%, 3% Surgiscreen¿¡¼ 10.1%·Î ³ªÅ¸³µ´Ù.
°á·Ð: Dia ¼±º°Ç÷±¸¸¦ Ãß°¡·Î °Ë»çÇÏ´Â ±âÁ¸ÀÇ ½Ã¾à°ú 3-Cell panel·Î Á¦ÀÛµÈ 3% Surgiscreen´Â ºñ½ÁÇÑ ºñ¿¹±âÇ×ü ¼±º°°Ë»ç ¾ç¼ºÀ²°ú Ç×-Dia Ç×üÀÇ ¾ç¼ºÀ²À» º¸ÀÌ¸ç °á°úÀÇ ³ôÀº ÀÏÄ¡µµ¸¦ º¸¿©ÁÖ¾ú´Ù.
Background: The Dia antigen has been found to have a relatively higher incidence among Korean populations. However, the current popular antibody screening panels contain no Dia positive cells. To prevent hemolytic transfusion reaction, screening for unexpected antibody plus screening for Dia positive cells should be performed. In this study, we evaluate the performance of the 3% Surgiscreen Sub-code D (Ortho-Clinical Diagnostics, USA) manufactured as a 3-cell panel including Dia cell versus the ID-DiaCell I-II (DiaMed, Switzerland) as a 2-cell panel plus ID-DiaCell Dia£« (DiaMed, Switzerland) in screening for irregular red blood cell alloantibodies.
Methods: From December 13, 2013 to April 24, 2014, we tested the 3% Surgiscreen by the AutoVue Innova system and the ID-DiaCell in parallel to evaluate reagent sensitivity in detecting irregular antibodies in multi-transfused patients¡¯ plasma or serum. Identification of unexpected antibody tests was performed for positive screening results.
Results: Antibody-positive rates were 4.2% (79/1885) and 4.6% (87/1885) for antibody screening with the 3% Surgiscreen and the ID-DiaCell, respectively. Among the 1885 samples, 1875 (99.5%) showed concordant results between the 2 methods, while 10 results differed. From the 10 discrepancies, 1 result was positive only on the 3% Surgiscreen. The prevalence of anti-Dia antibody was 10.1% and 9.2% in the 3% Surgiscreen and the ID-DiaCell, respectively.
Conclusion: The 3% Surgiscreen manufactured as 3-cell showed a high concordance rate ompared to standard methods. The prevalence of anti-Dia showed no difference between the 2 reagents. (Korean J Blood Transfus 2015;26:47-53)
¿ä¾à
Å°¿öµå
Dia antigen, anti-Dia, 3% Surgiscreen, Unexpected antibody screening test, Multiple transfused patients
KMID :
0387720150260010047
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The 3% Surgiscreen manufactured as 3-cell showed a high concordance rate ompared to standard methods.